Novartis has announced its acquisition of Anthos Therapeutics, a Boston-based biopharmaceutical company focused on developing abelacimab, an inve ...

About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathwayAbelacimab is currently in P ...

A new technology developed at MIT enables scientists to label proteins across millions of individual cells in fully intact 3D ...

MIT researchers introduce CuRVE, a protein-labeling technique enabling uniform staining across entire tissues.

Librela (bedinvetmab injection) is a monthly injectable monoclonal antibody, for which real-world drug experience data has ...

Zoetis (ZTS) announced that it has updated the U.S. label for Librela, following its submission of a supplement to the FDA. This supplement ...

Zoetis Inc. today announced that it has updated the U.S. label for Librela® (bedinvetmab injection), following its submission ...

FDA published two final guidance documents related to food allergens: Questions and Answers Regarding Food Allergens, ...

Uniform protein labeling in intact tissues is a challenge. An approach that allows antibodies to seep within organs could ...

including small molecules and antibody-drug conjugates. “Our long-standing commitment to the genitourinary cancer community has been foundational in our mission to transform the treatment ...

A new technology developed at MIT enables scientists to label proteins across millions of individual cells in fully intact 3D tissues with unprecedented speed, uniformity, and versatility.